A groundbreaking discovery in cardiac research has the potential to revolutionize heart disease treatment, offering a new path forward that could reduce the need for heart transplants and implanted devices. This exciting development, published in Nature Regenerative Medicine, reveals how the gene for Cyclin A2 (CCNA2) can be reactivated to promote cardiac repair in adult human heart cells.
The study, led by Dr. Hina Chaudhry, builds upon her previous work demonstrating heart regeneration in pigs after a heart attack. Now, the focus shifts to humans, with a translational bridge that utilizes a human-compatible viral vector to safely trigger cell division in adult human heart cells.
"Heart disease is a global concern, yet adult human heart muscle cells have long been believed to stop dividing after birth," Dr. Chaudhry explains. "Our research challenges this notion, showing that even middle-aged adult human heart cells can be encouraged to divide and form new, functional cells. This shifts the focus from symptom management to actual heart repair."
The research team developed a replication-deficient virus tailored for human use, delivering CCNA2 to heart muscle cells from healthy donor hearts. Through time-lapse imaging, they observed successful cell division, with the heart cells maintaining their normal structure and function.
Interestingly, when analyzing hearts from donors aged 21, 41, and 55, Cyclin A2 therapy prompted cell division in the older hearts but not in the youngest. This aligns with previous studies suggesting that younger hearts have inherent regenerative capabilities.
The daughter cells resulting from this process retained their structural proteins and normal calcium activity, indicating their functionality. Further analysis revealed that CCNA2 temporarily reactivates specific growth genes, facilitating heart repair without causing harmful thickening of heart tissue.
"This work is the culmination of years of dedication," Dr. Chaudhry shares. "We've brought our vision of heart regeneration through dormant cell division gene reactivation closer to reality. Our aim is to develop a therapy that empowers the heart to heal itself after injury or failure, reducing reliance on transplants or mechanical interventions."
The next phase involves seeking FDA approval to initiate clinical trials of CCNA2 therapy in patients with heart disease, bringing this innovative treatment one step closer to becoming a reality.
